0.3823  -0.01 (-2.47%)		09-15 16:00
Open: 0.3801 High: 0.4151 Volume: 1,026,492		Pre. Close: 0.392 Low: 0.3339 Market Cap: 4(M)

Short term
Mid term
Targets	6-month :	0.56	1-year :	0.68
Resists	First :	0.48	Second :	0.58
Pivot price	0.48
Supports	First :	0.33	Second :	0.27
MAs	MA(5) :	0.42	MA(20) :	0.49
	MA(100) :	0.66	MA(250) :	0.76
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	18.4	D(3) :	14.2
RSI	RSI(14): 19.1
52-week	High :	1.5	Low :	0.33

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PMCB ] has closed below the lower bollinger band by 3.0%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 30.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.42 - 0.42	0.42 - 0.42
Low:	0.33 - 0.33	0.33 - 0.33
Close:	0.38 - 0.38	0.38 - 0.39

PharmaCyte Biotech, Inc. is a biotechnology firm dedicated to the development and commercialization of advanced cellular therapies within the United States. Their primary therapeutic areas include various forms of cancer, diabetes, and malignant ascites. Central to their efforts is Cell-in-a-Box, their proprietary encapsulation technology which utilizes cellulose to enclose live cells. This innovative platform serves as the foundation for treatments aimed at diverse cancers, such as advanced and inoperable pancreatic cancer, as well as diabetes. The company's pipeline includes therapies for pancreatic and other solid cancerous tumors; a treatment for Type 1 and insulin-dependent Type 2 diabetes involving encapsulated, genetically modified insulin-producing cells; and cancer treatments derived from cannabis plant compounds. To further its research, PharmaCyte maintains collaborative agreements: one with the University of Technology, Sydney, for the creation of melligen cells to combat diabetes, and another with the University of Northern Colorado, focusing on methods for identifying, separating, and quantifying cannabis constituents. Originally established in 1996, the company operated under the name Nuvilex, Inc. before rebranding as PharmaCyte Biotech, Inc. in January 2015. Its corporate headquarters are located in Las Vegas, Nevada.

Mon, 14 Sep 2026
PharmaCyte Biotech 2026: Revenue $0 Net income ($5.79M), EPS ($0.54) — 10-Q Summary - TradingView

Mon, 14 Sep 2026
PharmaCyte (NASDAQ: PMCB) risks delisting if its stock stays below $1 - Stock Titan

Mon, 14 Sep 2026
PMCB 10-Q Filings - PharmaCyte Biotech, Inc. SEC 10-Q - Stock Titan

Sat, 22 Aug 2026
PMCB - PharmaCyte Biotech Inc Forecast, Target Price - Finviz

Wed, 19 Aug 2026
PharmaCyte (PMCB) Financial Results: The Company Lists Its Latest Available Figures in the Current Update; Market Reaction: Shares Move 1.58% Higher - Quarterly Profit Report - Vinanet

Tue, 18 Aug 2026
PharmaCyte (PMCB) Share-Price Review: Slides 4.80% to $0.52 at the Close; Technical Focus: Price Remains Between $0.49 Support and $0.55 Resistance in the Current Update - Earnings Miss Risk - Vinanet

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	11 (M)
Shares Float	10 (M)
Held by Insiders	5.7 (%)
Held by Institutions	7.1 (%)
Shares Short	208 (K)
Shares Short P.Month	322 (K)

EPS	-2.77
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	3.14
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-6.5 %
Return on Equity (ttm)	-44.8 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-5 (M)
Levered Free Cash Flow	2 (M)

PE Ratio	-0.14
PEG Ratio	0
Price to Book value	0.12
Price to Sales	0
Price to Cash Flow	-0.8

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.